LYKALABS

Lyka Labs Share PriceLyka Labs

₹121.2
-2.75 (-2.22%)
As on 10 December, 2023 | 02:41 BSE: 500259 NSE: LYKALABSISIN: INE933A01014

Lyka Labs Performance

Day Range

  • Low 119.80
  • High 125.00
₹ 121.2

52 Week Range

  • Low 88.50
  • High 155.90
₹ 121.2
  • Open Price124.00
  • Previous Close123.95
  • Volume40025

Start SIP in Lyka Labs

Start SIP

Lyka Labs Share Price

  • Over 1 Month 11.14%
  • Over 3 Month 7.11%
  • Over 6 Month 15.98%
  • Over 1 Year -11.66%

Lyka Labs Key Statistics

P/E Ratio -25.3
PEG Ratio 0.3
Market Cap Cr 401
Price to Book Ratio 8.8
EPS -1.9
Dividend 0
Relative Strength Index 48.44
Money Flow Index 81.14
MACD Signal 3.81
Average True Range 5.81

Lyka Labs Investment Rating

  • Master Rating:
  • Lyka Labs has an operating revenue of Rs. 90.92 Cr. on a trailing 12-month basis. An annual revenue de-growth of -51% needs improvement, Pre-tax margin of -14% needs improvement, ROE of -29% is poor and needs improvement. The company has a high debt to equity of 138%, which can be a reason to worry. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 8% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 20 which is a POOR score indicating inconsistency in earnings, a RS Rating of 33 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 68 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Lyka Labs Financials
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 27211917222228
Operating Expenses Qtr Cr 23191715171616
Operating Profit Qtr Cr 43325612
Depreciation Qtr Cr 3333339
Interest Qtr Cr 1133333
Tax Qtr Cr 00000013
Net Profit Qtr Cr 0-2-3-1000-15
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 84167
Operating Expenses Annual Cr 6567
Operating Profit Annual in Cr 1697
Depreciation Cr 1415
Interest Annual Cr 1220
Tax Annual Cr 020
Net Profit Annual Cr -1340
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 777
Cash from Investing Activity Annual Cr 7-4
Cash from Financing Annual Activity Cr -20-63
Net Cash Flow Annual Cr -79
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 7845
Fixed Assets Annual Cr 82108
Total Non Current Assets Annual Cr 137161
Total Current Assets Annual Cr 4248
Total Assets Annual Cr 179209
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 2515
ROE Annual % -1790
ROCE Annual % 474
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2461
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 28232218262735
Operating Expenses Qtr Cr 24201916202123
Operating Profit Qtr Cr 43325613
Depreciation Qtr Cr 4333449
Interest Qtr Cr 1133333
Tax Qtr Cr 00000013
Net Profit Qtr Cr 0-2-3-1101-15
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 96196
Operating Expenses Annual Cr 7693
Operating Profit Annual in Cr 17101
Depreciation Cr 1417
Interest Annual Cr 1220
Tax Annual Cr 021
Net Profit Annual Cr -1339
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 979
Cash from Investing Activity Annual Cr 7-6
Cash from Financing Annual Activity Cr -22-63
Net Cash Flow Annual Cr -510
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 4714
Fixed Assets Annual Cr 84112
Total Non Current Assets Annual Cr 107133
Total Current Assets Annual Cr 4452
Total Assets Annual Cr 152186
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 155
ROE Annual % -29292
ROCE Annual % 5100
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2253

Lyka Labs Technicals

EMA & SMA

Current Price
₹121.2
-2.75 (-2.22%)
pointer
  • Bullish Moving Average
  • ___
  • 8
  • Bearish Moving Average
  • ___
  • 8
  • 20 Day
  • ₹123.68
  • 50 Day
  • ₹119.47
  • 100 Day
  • ₹116.73
  • 200 Day
  • ₹116.57
  • 20 Day
  • ₹123.55
  • 50 Day
  • ₹118.12
  • 100 Day
  • ₹115.60
  • 200 Day
  • ₹111.61

Lyka Labs Resistance and Support

PIVOT
₹122.
Resistance
First Resistance 124.20
Second Resistance 127.20
Third Resistance 129.40
RSI 48.44
MFI 81.14
MACD Single Line 3.81
MACD 2.64
Support
First Resistance 119.00
Second Resistance 116.80
Third Resistance 113.80

Lyka Labs Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 41,703 4,170,300 100
Week 83,931 8,393,140 100
1 Month 342,121 18,002,400 52.62
6 Month 183,138 9,706,311 53

Lyka Labs Result Highlights

Lyka Labs Synopsis

NSE-Medical-Generic Drugs

Lyka Labs is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 80.59 Cr. and Equity Capital is Rs. 30.69 Cr. for the Year ended 31/03/2023. Lyka Labs Ltd. is a Public Limited Listed company incorporated on 29/12/1976 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1976PLC008738 and registration number is 008738.
Market Cap 401
Sales 85
Shares in Float 1.49
No of funds 14
Yield
Book Value 4.87
U/D Vol ratio 1.7
LTDebt / Equity 82
Alpha -0.03
Beta 0.62

Lyka Labs

Owner NameSep-23Jun-23Apr-23Mar-23
Promoters 54.81%54.58%54.56%51%
Mutual Funds 0.01%0.01%2.69%3.31%
Insurance Companies 0.4%0.4%0.4%0.43%
Foreign Portfolio Investors 0.18%0.17%0.17%0.18%
Financial Institutions/ Banks
Individual Investors 35.5%35.56%33.03%35.08%
Others 9.1%9.28%9.15%10%

Lyka Labs Management

Name Designation
Mr. Babulal Jain Chairman
Mr. Kunal Gandhi Managing Director & CEO
Mr. Yogesh B Shah Executive Director & CFO
Mr. Sandeep P Parikh Independent Director
Mrs. Dhara P Shah Independent Director
Mr. Prashant Godha Non Executive Director
Mr. Shashil Mendosa Non Executive Director

Lyka Labs Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Lyka Labs Corporate Action

Date Purpose Remarks
2023-11-02 Quarterly Results
2023-08-02 Quarterly Results
2023-05-23 Audited Results
2023-04-18 Others
2023-02-07 Quarterly Results

Lyka Labs MF Shareholding

Name Amount(cr)
Quant Active Fund Growth 6,681

Lyka Labs FAQs

What is Share Price of Lyka Labs ?

Lyka Labs share price is ₹121 As on 10 December, 2023 | 02:27

What is the Market Cap of Lyka Labs ?

The Market Cap of Lyka Labs is ₹401.1 Cr As on 10 December, 2023 | 02:27

What is the P/E ratio of Lyka Labs ?

The P/E ratio of Lyka Labs is -25.3 As on 10 December, 2023 | 02:27

What is the PB ratio of Lyka Labs ?

The PB ratio of Lyka Labs is 8.8 As on 10 December, 2023 | 02:27

Q2FY23